共查询到19条相似文献，搜索用时 171 毫秒
1.
本试验采用以SV40早期启动子控制的大肠杆菌β—半乳糖苷酶(LacZ)基因作为报告基因,将其插入到含有火鸡疮疹病毒(HVT)糖蛋白A(gA)抗原基因的克隆片段中,构建成HVT转移载体质粒,在该转移载体质粒中,大肠杆菌LacZ基因的两端分别与两段1.4kb和1.8kb的HVT同源片段相连,克隆于pUC19质粒中,将含有LacZ基因的载体质粒与感染HVT的鸡胚成纤维细胞(CEF)中提取的全细胞DNA共同转染CEF,待病毒蚀斑出现后,用含有X-gal的琼脂糖覆盖细胞单层,可见到有兰色的病毒蚀斑,这些结果表明外源性的LacZ基因已被重组到HVT DNA中,同时还证明HVT的gA基因与HVT的复制无关,可以用于外源基因的插入和表达。 相似文献
2.
《中国预防兽医学报》2017,(11)
为构建同时表达禽流感病毒(AIV)HA蛋白及传染性法氏囊病毒(IBDV)VP2蛋白的重组火鸡疱疹病毒(r HVT),本研究以本实验室构建的连续覆盖火鸡疱疹病毒(HVT)全基因组的5个重组粘粒(p Fos A、p Fos B、p Fos C、p Fos D和p Fos E)为基础,利用猪捷申病毒2A蛋白的编码序列,将HA基因和VP2基因串联,并克隆于p CAGGs载体中,构建重组质粒p CA-HA-2A-VP2。利用Gateway LR克隆技术,将重组质粒中的HA-2A-VP2的表达盒(Pec-HA-2A-VP2-POLYA)插入到p Fos C粘粒中HVT片段的复制非必需区HVT053与HVT054基因之间,构建重组粘粒p Fos C-5354-HA-VP2。将p Fos A、p Fos B、p Fos D、p Fos E和p Fos C-5354-HA-VP2 5个重组粘粒共转染鸡胚成纤维细胞(CEF),制备表达HA蛋白及VP2蛋白的重组火鸡疱疹病毒(r HVT-5354-HA-VP2)。将重组病毒在CEF中连续传至20代后,通过PCR、间接免疫荧光和western blot鉴定分析,结果显示HA与VP2基因能够在重组病毒中稳定存在并正确表达;生长动力学结果表明,重组病毒在CEF中的增殖效率与野生型病毒HVT无显著差异。该重组病毒的制备为研制AIV-IBDV-马立克病毒三联苗奠定了基础。 相似文献
3.
本实验以独立启动子控制的增强型绿色荧光基因(GFP)作为报告基因,同时将CMV启动子及其多克隆位点与之连接,构成外源基因表达盒,插入到马立克病毒(MDV)复制非必需区基因(短独特区US2等)构成的同源臂中,构建成重组马立克病毒的通用载体。鉴定正确后,将转移载体与提取的MDV基因组共转染鸡胚成纤维细胞(CEF),同源重组获得具有感染性的重组病毒,待病毒蚀斑出现后,荧光显微镜下观察,可见到明显的绿色荧光病毒蚀斑,经三次筛选,初步分离到重组病毒。结果表明,转移载体与MDV基因组共转染可获得感染性病毒,US2基因可作为重组病毒构建中的外源基因插入位点,证实通用转移载体的构建是可行的,为重组马立克病毒新型疫苗的研究奠定物质基础。 相似文献
4.
《中国兽医学报》2020,(2)
根据GenBank中公布的猪伪狂犬病病毒(porcine pseudorabies virus,PRV)US区基因序列(KJ789182),设计2对特异性引物,扩增PRV NY株gE/gI基因两侧序列,克隆至pUC-19载体,构建转移质粒pUC-gE/gILR,同时插入绿色荧光蛋白(EGFP)标记基因,构建转移质粒pUC-gE/gILRE,作为重组同源臂。以PRV NY流行株为亲本株,将其基因组与转移质粒pUC-gE/gILRE共转染ST细胞,通过筛选绿色荧光蚀斑,获得含有荧光蛋白的重组病毒rPRV NY-gE~-/gI~--EGFP~+。再以该毒株基因组与转移质粒pUC-gE/gILR进行同源重组,通过筛选无荧光蚀斑,纯化重组病毒,经PCR扩增、测序,证实获得了去除EGFP基因的重组病毒rPRV NY-gE~-/gI~-。该重组病毒在ST细胞上培养时,与亲本株PRV NY具有相似的生长曲线,但该重组病毒的体外生长动力学比亲本株弱。本研究成功构建了1株针对目前PRV流行株的gE/gI双基因缺失病毒,为我国根除PR提供技术支持。 相似文献
5.
为构建表达禽流感病毒(AIV)血凝素(HA)基因的重组疱疹病毒(HVT),本研究将AIV A/Goose/Guangdong/3/96(H5N1)的HA基因克隆于真核表达质粒中,构建了转移载体pUAB-gpt-HA。通过同源重组及霉酚酸筛选技术,将HA基因表达盒插入到HVT US10基因区,构建了一株表达H5亚型AIV HA基因的重组病毒HVT(rHVT-US10-HA)。经PCR、间接免疫荧光、western blot及红细胞凝集试验鉴定,重组病毒能稳定表达具有生物学活性的HA蛋白。rHVT-US10-HA的构建为禽流感基因工程病毒活载体疫苗的研究奠定了基础。 相似文献
6.
鸡传染性法氏囊病（IBD）是一种严重危害养禽业的高度致死性和免疫抑制性传染病。为研制IBD重组火鸡疱疹病毒（HVT）活载体疫苗,本研究构建了表达鸡传染性法氏囊病病毒（IBDV）保护性抗原VP2基因的重组HVT并对其体外生物学特性进行了分析。通过RT-PCR扩增IBDV超强毒株VP2基因并克隆入pCI载体,获得重组真核表达质粒pCI-VP2。用限制性内切酶将携带CMV启动子的VP2基因表达框架切下,连接于入门质粒pENTR,构建获得重组入门质粒pENTR-VP2。将pENTR-VP2与HVT重组黏粒H3-Kan/ccdB进行LR重组反应,构建重组表达黏粒H3-VP2。用H3-VP2与其他4个相互重叠并覆盖HVT全基因组的黏粒共同转染鸡胚成纤维细胞（CEF）,拯救获得重组病毒rHVT-VP2。将重组病毒在CEF中连续传至20代后用PCR、间接免疫荧光试验和免疫印迹试验进行检测,并绘制重组病毒体外生长曲线,分析其体外复制特性。结果表明,重组病毒rHVT-VP2能够稳定表达VP2蛋白,rHVT-VP2在CEF中的复制能力与亲本病毒无明显差异。重组病毒rHVT-VP2免疫鸡后能够诱导产生IBDV中和抗体,并对IBDV强毒株攻击引起的死亡提供90%免疫保护。重组病毒rHVT-VP2的构建为研制IBD重组HVT活载体疫苗奠定了基础,对IBD的防控具有重要意义。 相似文献
7.
《中国兽医学报》2015,(9):1422-1428
为了获得表达猪细小病毒(PPV)VP2蛋白和细胞因子猪白细胞介素-18(IL-18)的重组猪伪狂犬病毒(PRV)。将PPV VP2基因和猪IL-18基因分别插入到PRV转移质粒PG中,得到重组质粒PG18-VP2。利用脂质体转染法将重组转移质粒PG18-VP2与猪PRV弱毒株DNA共转染猪睾丸(ST)细胞,以EGFP荧光标记,通过5轮蚀斑筛选纯化,成功获得表达PPV VP2蛋白和猪IL-18且带EGFP标记的重组伪狂犬病毒IL18-VP2-rPRV。用重组病毒感染ST细胞,12h后在荧光显微镜下可见明亮的绿色荧光;通过RT-PCR证实感染细胞中含有PPV VP2和猪IL-18mRNA;Western-blot试验结果显示,重组病毒能表达具有生物活性的PPV VP2蛋白和猪IL-18。重组病毒经连续20次传代后感染细胞仍能发出绿色荧光,PCR检测表明VP2及IL-18基因在重组病毒中能稳定遗传。为进一步研究表达PPV VP2蛋白和猪IL-18的重组猪伪狂犬病毒的免疫效力奠定了基础。 相似文献
8.
《中国预防兽医学报》2015,(5)
为鉴定鸭肠炎病毒(DEV)的非必需基因,本研究利用增强型绿色蛋白(EGFP)基因为报告基因,通过在转染的鸡胚成纤维细胞(CEF)中同源重组,将其插入DEV基因组的TK基因中,经筛选和纯化绿色荧光病毒蚀斑,获得表达EGFP的重组DEV,命名为r DEVTK-EGFP。对重组病毒与亲本病毒DEV Clone-03复制动力学比较结果显示,重组病毒滴度显著低于亲本病毒(p0.01)。对重组病毒在复制过程中感染细胞能力和荧光表达时相检测结果表明,在感染后48 h~72 h表达荧光信号细胞明显增多,该结果与重组病毒复制动力学一致。将重组病毒在CEF中连续传代至20代,仍具有遗传稳定性。该研究结果表明,TK基因为DEV复制非必需基因,可以作为外源基因插入位点,用于禽用新型基因工程疫苗的研制。 相似文献
9.
将新城疫病毒（NDV）F48E9株融合蛋白（F）基因1700bp克隆到真核表达载体pcDNA3中，构建成表达F基因的载体pc3F。然后将包含F基因及其上游的细胞巨化病毒启动子和增强子的3800bp DNA片段再克隆入包含火鸡疱疹病毒（HVT）非必须片段载体pTK2B中，构建成功含有F基因表达盒的HVT转移质粒体pTK3F。经限制性内切酶酶切分析，F基因表达盒的插入方向与pTK2B中TK基因转录方向一致。该研究为进一步在细胞中转染并获得表达F基因的HVT重组病毒奠定了基础。 相似文献
10.
《中国家禽》2017,(1)
启动子在重组火鸡疱疹病毒(HVT)载体疫苗中起着至关重要的作用,内源性启动子活性较弱,受载体病毒自身的复制调控。研究通过预测分析HVT(FC126株)囊膜糖蛋白(g B)启动子,将其克隆并与经密码子优化的H7N9亚型禽流感病毒的HA基因构建表达盒质粒,再进一步通过间接免疫荧光试验和荧光定量PCR比较其与外源性强启动子CMV和马立克氏病病毒(MDV,CVI988株)g B启动子的转录表达活性。结果表明:3种启动子均能使目的基因在体外获得转录表达,CMV启动子的活性高于内源性g B启动子,而HVT的g B与MDV的g B表达活性差异不显著。研究结果为重组HVT载体疫苗启动子的选择提供了一定参考。 相似文献
11.
12.
B R Cho 《Avian diseases》1981,25(4):839-846
The growth and plaque formation by turkey herpesvirus (HVT) amd Marek's disease herpesvirus (MDHV) were examined in QT35 cells, a continuous fibroblast cell line derived from chemically induced tumors of Japanese quail. HVT grew and formed plaques consistently in QT35 cells when inoculated with cell-culture-propagated virus or peripheral mononuclear leukocytes (PML) from chickens that had been inoculated with HVT. Both oncogenic and nononcogenic strains of MDHV, however, failed to grow and induced neither plaques nor cytopathic effects in QT35 cells, whether inoculated with cell-culture-grown virus or heavily infected PML. When PML from chickens infected with both HVT and MDHV were assayed, only HVT plaques had developed, despite the presence in the inocula of high levels of MDHV with less HVT. The QT35 cell line provides a simple in vitro system for differentiating between HVT and MDHV and for selective isolation and identification of HVT from chickens infected with both HVT and MDHV. 相似文献
13.
采用PCR方法，以传染性贫血病毒(CIAV)DNA为模板，扩增并克隆了CIAV的VP1、VP2基因，并进行了序列分析。经基因修饰，将这两个基因分别加上表达元件后连接作为目的基因。通过同源重组技术，将目的基因插入到火鸡疱疹病毒(HVT)gC基因区，构建了一株含CIAV VP1、VP2基因表达单元的重组HVT(VP1VP2-rHVT)：体内、体外传代结果表明该重组病毒性状稳定。采用PCR扩增及Southem blot杂交检测，证实了CIAV VP1、VP2基因的插入。 相似文献
14.
Studies were made to determine whether infectious bursal disease virus (IBDV) infection would affect the response of chickens to turkey herpesvirus (HVT) vaccination in the development and level of HVT viremia and virus-neutralizing (VN) antibodies to HVT. The HVT viremia in the vaccinated chickens was not affected by IBDV, whether IBDV was inoculated simultaneously with HVT vaccination at one day of age or whether it was inoculated 3 weeks postvaccination with HVT. However, VN antibody response to HVT was significantly suppressed (P less than 0.001) when vaccinated chickens were exposed to IBDV either at the time of vaccination or at 3 weeks postvaccination. Such immunosuppression by IBDV of VN antibody response to HVT vaccination may result in a reduced antiviral immunity against Marek's disease virus. 相似文献
15.
Turkey herpesvirus (HVT) was isolated from the kidneys of 6 of 8 turkey poults from two flocks. The isolates were identified by syncytial-type of cytopathology, inhibition of plaque formation by 5-bromodeoxyuridine, formation of Cowdry type A intranuclear inclusions in cell cultures, and presence of herpes-type virions in negatively stained preparations and thin sections of infected cell cultures. One of these isolates inoculated into chickens proved apathogenic over an observation period of 10 weeks. Indirect immunofluorescence and serum neutralisation tests revealed serological relationship between these isolates and the strain NSW 1/70 of HVT. Staining of HVT-infected cell culture by Marek's disease herpesvirus (MDHV) antiserum showed intranuclear fluorescence but attempts to prepare HVT precipitating antigen or to demonstrate cross-precipiation between HVT and MDHV were unsuccessful. 相似文献
16.
Vaccination of chickens with turkey herpesvirus (HVT) or attenuated Marek's disease herpesvirus (aMDHV) blocked infection with virulent MDHV (VMDHV) for approximately 5 weeks after contact exposure. However, there was no apparent blockage of infection when challenge virus was administered intraabdominally (IA). Evidence for infection with VMDHV was based on viral isolation by in vivo assay or by detecting precipitins to "A" antigen associated with virulent virus. The HVT stimulated production of neutralizing antibody against VMDHV in a high percentage of chickens, whereas the aMDHV was a comparatively poor inducer of such antibody. Despite this difference, both of the vaccinal viruses conferred protection against development of Marek's disease. 相似文献
17.
为研究具有不同抗性的马立克氏病(MD)疫苗免疫鸡羽髓后,疫苗毒和超强毒(vvMDV)的复制动力学及两种病毒载量的相关性,本实验对经火鸡疱疹病毒(HVT)FC126疫苗株免疫1周后(1wpv),攻击vvMDV Md5株G3系和G7系鸡羽髓中的HVT和vvMDV载量进行定量检测及相关性分析。结果显示,G3系和G7系鸡群羽髓中的vvMDV载量始终高于疫苗毒。其中,G3系鸡群在免疫和攻毒后的相同时间内,疫苗毒与vvMDV载量的消长规律基本一致,均在感染后第4周(4wpi)出现峰值,6wpi降至最低水平,两种病毒载量多表现为正相关,6wpv～8wpv为持续显著正相关;G7系的两种病毒的复制动力学存在差异:vvMDV载量从攻毒后第6周呈增长趋势,而疫苗毒在4wpv出现峰值后迅速下降,两种病毒载量多表现为负相关。本研究表明,免疫遗传基因在对病毒的抵抗中起主要作用,为MDV的感染机制和疫苗免疫机理的研究提供实验依据。 相似文献
18.
The average percentage of acid alpha naphthyl acetate esterase reacting lymphocytes (APARL) was enumerated in the peripheral blood of chickens challenged with Marek's disease after vaccination with either turkey herpesvirus (HVT), inactivated Marek's disease virus (IMDV) or a mixture of the two (bivalent vaccine). A gradual increase in APARL value was noticed in the vaccinated chickens from day 7 to 70 after challenge with a virulent Marek's disease virus. The increase was consistent and significantly higher in bivalent (HVT plus IMDV) than in HVT-vaccinated chickens while the slight increase noticed in IMDV vaccinated-challenged birds was inconsistent. 相似文献
19.
OBJECTIVES: To examine the effects of varying the doses of turkey herpesvirus (HVT) vaccine and Marek's disease virus (MDV) challenge at two intervals after vaccination on the protection of chickens against challenge with MDV. DESIGN AND PROCEDURE: Experiment 1, a dose response study, consisted of 11 doses of HVT vaccine administered at hatch followed by challenge with 100 plaque forming units (pfu) of MDV 5 days post vaccination. Experiment 2, a 2 x 6 x 2 factorial design, included two HVT vaccine types, six different doses of HVT vaccine and 50 pfu and 200 pfu of MDV challenge 2 days post vaccination. All chickens were reared up to day 56 post challenge when all survivors were killed humanely. Dead and killed chickens were examined for gross MD tumours. RESULTS: Experiment 1 showed a significant positive linear relationship between dose of HVT vaccine and protective index in chickens challenged 5 days post vaccination. However the range of protective index observed was limited. In Experiment 2 neither HVT vaccine provided significant protection at any dose. There was no significant effect of vaccine type or MDV challenge dose on overall protection against challenge. Chickens challenged with 200 pfu of MDV had significantly higher mortality and MD incidence than those with 50 pfu. CONCLUSIONS: HVT vaccine dose had a significant impact on protective index, but vaccination to challenge interval appeared to have greater impact on the protective efficacy of vaccination. A fourfold increase in challenge dose increased mortality rate and incidence of MD. 相似文献